NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,425.00 -0.90 (-0.04%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,930.28 +162.48 (+0.30%)
Movano Inc. (MOVE)
After hours:
- PR Newswire
Movano Health Reports Q1 2024 Financial Results and Provides Business Update
Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported first quarter 2024 results and provided a business update.
- PR Newswire
Movano Health Submits Exemplary Sp02 Clinical Trial Results in Key Step Towards FDA 510(k) Clearance Decision
Movano Health (Nasdaq: MOVE) announced that it successfully submitted updated pivotal clinical trial results as well as proof of enhanced medical device usability on April 22, 2024 to the U.S. Food and Drug Administration (FDA) as part of its 510(k) filing for the Company's first commercial medical device, the Evie Med Ring pulse oximeter. An FDA clearance would bring Movano Health a significant step closer in its pursuit to disrupt the wearables industry while unlocking significant partnership
- PR Newswire
Movano Health to Report First Quarter 2024 Financial Results on Wednesday May 15, 2024
Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report first quarter 2024 financial and operating results on Wednesday May 15, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET.
